Talis Biomedical 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rob Kelley

최고 경영자

US$1.0m

총 보상

CEO 급여 비율	54.1%
CEO 임기	2.9yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14

CEO 보상 분석

Rob Kelley 의 보수는 Talis Biomedical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$51m
Mar 31 2024	n/a	n/a	-US$57m
Dec 31 2023	US$1m	US$551k	-US$62m
Sep 30 2023	n/a	n/a	-US$75m
Jun 30 2023	n/a	n/a	-US$86m
Mar 31 2023	n/a	n/a	-US$98m
Dec 31 2022	US$2m	US$525k	-US$113m
Sep 30 2022	n/a	n/a	-US$115m
Jun 30 2022	n/a	n/a	-US$127m
Mar 31 2022	n/a	n/a	-US$165m
Dec 31 2021	US$2m	US$322k	-US$192m
Sep 30 2021	n/a	n/a	-US$208m
Jun 30 2021	n/a	n/a	-US$199m
Mar 31 2021	n/a	n/a	-US$144m
Dec 31 2020	US$2m	US$89k	-US$91m

보상 대 시장: Rob 의 총 보상 ($USD 1.02M )은 US 시장( $USD 646.00K ).

보상과 수익: Rob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Rob Kelley (52 yo)

2.9yrs

테뉴어

US$1,019,331

보상

Mr. Robert Kelley, also known as Rob, MBA, has been Chief Executive Officer and Director of Talis Biomedical Corporation since December 8, 2021 and served as its Chief Commercial Officer since September 20...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Kelley	CEO & Director	2.9yrs	US$1.02m	0.037% $ 1.2k
Kimberly Popovits	Lead Independent Director	2.9yrs	US$117.10k	0.76% $ 23.4k
Randal Scott	Independent Director	8.8yrs	US$100.27k	6.3% $ 194.2k

2.9yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: TLIS 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Talis Biomedical 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors

Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director

Less than half of directors are independent

Talis Biomedical Corporation Announces Resignation of Raymond Cheong from Board of Directors

Less than half of directors are independent

Talis Biomedical Corporation Announces Board Changes

Recent updates

Talis Biomedical Corporation Files Form 15

Talis Biomedical Corporation(OTCPK:TLIS) dropped from NASDAQ Composite Index

Talis Biomedical Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5101

Talis Biomedical Corporation announced delayed 10-Q filing

Talis Biomedical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels

Talis Biomedical Announces 1-For-15 Reverse Stock Split to Regain Compliance

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors

Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director

Talis Biomedical Corporation to Report Q1, 2023 Results on May 11, 2023

Talis Biomedical Transfers the Listing of Its Securities to the Nasdaq Capital Market

Price target decreased to US$0.40

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.98 loss per share (vs US$1.49 loss in 3Q 2021)

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Talis Biomedical reports Q2 results

Talis Biomedical Corporation Announces Resignation of Raymond Cheong from Board of Directors

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.25

Less than half of directors are independent

Talis Biomedical Corporation Announces Board Changes

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Talis Biomedical Aims For Manufacturing Turnaround

Talis Biomedical Corporation to Report Q4, 2021 Results on Mar 15, 2022

The Klein Law Firm Announces Lead Plaintiff Deadline of March 8, 2022 in the Class Action Filed on Behalf of Talis Biomedical Corporation Shareholders

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Talis Biomedical Corporation

Levi & Korsinsky, LLP Notifies Shareholders of Talis Biomedical Corporation of A Class Action Lawsuit and A Lead Plaintiff Deadline

Glancy Prongay & Murray LLP Files Securities Lawsuit Against Talis Biomedical Corporation

Less than half of directors are independent

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$13.90 loss in 3Q 2020)

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates fall to US$11.2m

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Talis Biomedical Corporation(NasdaqGM:TLIS) dropped from Russell Microcap Growth Index

Independent Director recently bought US$203k worth of stock

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2021 earnings released: US$4.61 loss per share (vs US$56.61 profit in 1Q 2020)

Full year 2020 earnings released: US$42.98 loss per share (vs US$34.34 profit in FY 2019)

Talis Appoints Jeryl Hilleman to Board of Directors

Talis Biomedical Corporation Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of Its Talis One™ Covid-19 Test

Talis Biomedical Corporation has completed an IPO in the amount of $220.8 million.

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령